A dual-signal electrochemiluminescence immunosensor for high-sensitivity detection of acute myocardial infarction biomarker
Based on two different types of luminescence systems (Ru﹡(bpy)32+/TPA and SnO2 NFs/K2S2O8), a new type of electrochemiluminescence (ECL) immunosensor was prepared, which realized the detection of acute myocardial infarction biomarker cTnI. In this strategy, Ru(bpy)32+, above all, was immobilized on...
Saved in:
Published in | Biosensors & bioelectronics Vol. 194; p. 113591 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier B.V
15.12.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Based on two different types of luminescence systems (Ru﹡(bpy)32+/TPA and SnO2 NFs/K2S2O8), a new type of electrochemiluminescence (ECL) immunosensor was prepared, which realized the detection of acute myocardial infarction biomarker cTnI. In this strategy, Ru(bpy)32+, above all, was immobilized on the NH2-MIL-125 as a capture probe. Subsequently, cTnI and SnO2 NFs was bonded to the electrode surface through the interaction between antigen and antibody in turn. During this process, Ru(bpy)32+ and the co-reactant TPA first showed strong and stable ECL emission. As the concentration of cTnI in the test system increased, the signal of SnO2 NFs and the co-reactant K2S2O8 gradually enhanced, indicating self-calibrating mechanism of the assay system. Therefore, the “off-on” ECL immunosensor can be detected in the linear range of 10−5 -104 ng/mL, and the limit of detection (LOD) is 3.39 fg/mL (S/N = 3), respectively. The dual-signal electrochemiluminescence method has the advantages of low cost, simple analysis process, wide detection range and good selectivity, providing a promising analysis protocol for clinical applications.
•An self-calibrating ECL immunosensor based on Ru(bpy)32+/TPA and SnO2 NFs/K2S2O8 luminescence systems.•One-pot synthesis of Ru(bpy)32+@NH2-MIL-125 composites.•The dual-signal type ECL immunosensor can be applied for cTnI sensitive determination in human serum and blood samples. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0956-5663 1873-4235 |
DOI: | 10.1016/j.bios.2021.113591 |